Evaluation of radioiodinated quinazoline derivative as a new ligand for EGF receptor tyrosine kinase activity using SPECT

Annals of Nuclear Medicine

Volumn 25, Issue 2, 2011, Pages 117-124

  Hirata, Masahiko ^a   Kanai, Yasukazu ^a,b   Naka, Sadahiro ^a   Matsumuro, Keiji ^a   Kagawa, Shinya ^a,c   Yoshimoto, Mitsuyoshi ^d   Ohmomo, Yoshiro ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c Shiga Medical Center Research Institute   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

EGF; PD153035; Radiopharmaceutical; SPECT; Tyrosine kinase

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 IODOANILINO) 6,7 DIETHOXYQUINAZOLINE; 4 (3 IODOANILINO) 6,7 DIETHOXYQUINAZOLINE IODINE 125; ALPHA (3,4 DIMETHOXYBENZYLIDENE) 2 PYRIDYLACETONITRILE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; GENISTEIN; QUINAZOLINE DERIVATIVE; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DEIODINATION; DRUG BINDING SITE; DRUG CLEARANCE; DRUG RETENTION; DRUG STRUCTURE; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIODINATION; RADIOISOTOPE DISTRIBUTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR;

ANIMALS; CELL LINE, TUMOR; HUMANS; IODINE RADIOISOTOPES; LIGANDS; MALE; MICE; NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SUBSTRATE SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79954447002     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-010-0432-4     Document Type: Article

References (31)

1. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature. 1984;307:521-7. (Pubitemid 14135812)
2. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 1984;309:418-25. (Pubitemid 14102443)
3. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res. 2000;77:25-79. (Pubitemid 29439302)
4. Herbst RS, Fukuoka M, Baselga J. Gefitinib-a novel targeted approach to treating cancer. Nat Rev Cancer. 2004;4:956-65. (Pubitemid 39626219)
5. McLeod HL, Brunton VG, Eckardt N, Lear MJ, Robins DJ, Workman P, et al. In vivo pharmacology and anti-tumor evaluation of the tyrphostin tyrosine kinase inhibitor RG13022. Br J Cancer. 1996;74:1714-8.
6. Croisy-Delcey M, Croisy A, Mousset S, Letourneur M, Bisagni E, Jacquemin SA, et al. Genistein analogues: effects on epidermal growth factor receptor tyrosine kinase and on stress-activated pathways. Biomed Pharmacother. 1997;51:286-94. (Pubitemid 27296841)
7. Barker AJ, Gibson KH, Grundy W, Goldfrey AA, Barlow JJ, Healy MP, et al. Genistein analogues: effects on epidermal growth factor receptor tyrosine kinase and on stress-activated pathways. Bioorg Med Chem. 2001;11:1911-4.
8. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res. 2001;7:1459-65. (Pubitemid 32708703)
9. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002;62:5749-54. (Pubitemid 35204731)
10. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem. 2002;277:46265-72. (Pubitemid 35417619)
11. Grunwald V, Hidalgo M. Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774). Adv Exp Med Biol. 2003;532:235-46. (Pubitemid 37176791)
12. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994;265:1093-5. (Pubitemid 24293076)
13. Kunkel MW, Hook KE, Howard CT, Roberts BJ, Elliott WL, Leopold WR. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs. 1996;13:295-302.
14. Ramos SM, Rodríguez N, Oliva JP, Iznaga EN, Perera A, Morales A, et al. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: part III. Clinical trials safety and diagnostic efficacy. J Nucl Med. 1999;40:768-75. (Pubitemid 29210750)
15. Divgi CR, Welt S, Kris M, Real FX, Yeh SD, Gralla R, et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst. 1991; 83:97-104.
16. Goldenberg A, Masui H, Divgi C, Kamrath H, Pentlow K, Mendelsohn J. Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody. J Natl Cancer Inst. 1989;81:1616-25. (Pubitemid 19264044)
17. Johnstrom P, Fredrikson A, Thorell JO, Elander SS. Synthesis of [methoxy-11C] PD153035, a selective EGF receptor tyrosine kinase inhibitor. J Labelled Compd Radiopharm. 1998;41:623-9. (Pubitemid 28308258)
18. Seimbille Y, Phelps ME, Czernin J, Silverman DS. Fluorine-18 labeling of 6,7-distributed anilinoquinazoline derivatives, for positron emission tomography (PET) imaging of tyrosine kinase receptors: synthesis 18F-Iressa and related molecular probes. J Labelled Compd Radiopharm. 2005;48:819-27.
19. Mishani E, Abourbeh G, Jacobson O, Dissoki S, Daniel RB, Rozen Y, et al. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. J Med Chem. 2005;48:5337-48. (Pubitemid 41113919)
20. Abourbeh G, Dissoki S, Jacobson O, Litchi A, Ben DR, Laki D, et al. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl Med Biol. 2007;34:55-70. (Pubitemid 46038157)
21. Mishani E, Abourbeh G, Rozen Y, Jacobson O, Laky D, Iris DB, et al. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)quinazoline- 6-yl]amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors. Nucl Med Biol. 2004;31:469-76. (Pubitemid 38490746)
22. Van Brocklin HF, Lim JK, Coffing SL, Hom DL, Negash K, Ono MY, et al. Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. J Med Chem. 2005;48:7445-56. (Pubitemid 41743658)
23. Bridges AJ, Zhou H, Cody DR, Rewcastle GW, McMichael A, Showalter HDH, et al. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3- bromoanilino)-6,7-dimethoxyquinazoline (PD153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem. 1996;39:267-76.
24. Narla RK, Liu XP, Myers DE, Uckun FM. 4-(30-Bromo-40hydroxylphenyl)- amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. Clin Cancer Res. 1998;4:1405-14. (Pubitemid 28265222)
25. Wang H, Yu J, Yang G, Song X, Sun X, Zhao S, Mu D. Assessment of 11C-labeled-4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression. Cancer Sci. 2007;98:1413-6. (Pubitemid 47241765)
26. Liu N, Li M, Li X, Meng X, Yang G, Zhao S, et al. PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans. J Nucl Med. 2009;50:303-8.
27. Ward WHJ, Cook PN, Slater AM, Davis DH, Holdgate GA, Green LR. Epidermal growth factor receptor tyrosine kinase: investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol. 1994;48:659-66.
28. Bridges AJ, Cody DR, Zhou H, McMichael A, Fry DW. Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(phenethylamino)quinazolines. Bioorg Med Chem. 1995;3:1651-6. (Pubitemid 26022441)
29. Dai Q, Ling YH, Lia M, Zou YY, Kroog G, Iwata KK, et al. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin Cancer Res. 2005;11:1572-8. (Pubitemid 40315242)
30. Haigler HT, Ash JF, Singer SJ, Cohen S. Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells. Proc Natl Acad Sci USA. 1978;75:3317-21. (Pubitemid 8389718)
31. Bos J, Mendelsohn J, Kim YM, Albanell J, Fry DW. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 1997; 3:2099-106. (Pubitemid 27505138)